{"adverse_reactions":["ADVERSE REACTIONS The majority of side effects observed have been reversible and of a minor nature and include gastro-intestinal disorders (dyspepsia, abdominal pain, nausea), rash, ruber, urticaria, symptoms of enuresis, headache, dizziness, and drowsiness. To report suspected adverse reactions, call 1-800-FDA-1088."],"contraindications":["CONTRAINDICATIONS Patients with allergy to these drugs or other analogues (diclofenac). Patients with asthma. Like NSAIDS, acetylsalicylic acid and other drugs which inhibit prostagladin-synthesis may precipitate attacks of asthma, acute rhinitis or urticaria. Patients with active peptic ulcer."],"description":["DESCRIPTION White, oblong, film-coated tablet, engraved with \"UT\" on one side and \"CL CR\" on the other side."],"dosage_and_administration":["Dosage and Administration Adults: The recommended dose is 200 mg daily, taken as one dose (every 24 hours). However, the dose and dose frequency of CLANZA CR can be modified under the supervison of physician or pharmacist."],"drug_interactions":["DRUG INTERACTIONS There has been no drug interactions reported, but close monitoring of patients on combination with lithium and digoxin, oral antidiabetic agents, anticoagulants, diuretics, and other analgesics."],"effective_time":"20111102","general_precautions":["GENERAL PRECAUTIONS Patients suffering from dizziness, vertigo, or other central nervous system disorders while taking NSAIDS should refrain from driving or handling dangerous machinery."],"how_supplied":["PACKAGE 10 Blister Packs with 10 Tablets in each Blister Pack"],"id":"730de348-1686-4017-804e-010fd87b1f84","indications_and_usage":["INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism."],"openfda":{},"overdosage":["OVERDOSAGE There are no human data available on the consequences of CLANZA CR overdosage. If overdosage is observed, therapeutic measures should be taken according to symptoms; supportive and symptomatic treatment should be given for complications such as hypotension, gastro-intestinal irritation, respiratory depression, and convulsions."],"package_label_principal_display_panel":["label test Clanza Package Label"],"pediatric_use":["USE IN CHILDREN The dosage and indication is not established yet for children with less than 6 years old."],"precautions":["CAUTIONS Patients with symptoms indicative of gastro-intestinal disorders, with a history of gastroulceration. Patients with severe hepatic impairment or cardiac or renal impairment. Patients under the medication of diuretics. Patients in recovery after surgical treatment."],"pregnancy":["USE IN PREGNANCY AND NURSING MOTHERS Since there is no information on the safe use of CLANZA CR during pregnancy and lactation, the use of CLANZA CR should therefore be avoided in pregnancy and lactation."],"set_id":"8a023942-01e8-4849-aa3c-1a640ffc7fd3","spl_patient_package_insert":["Enter section text here"],"spl_product_data_elements":["Clanza CR Aceclofenac Aceclofenac Aceclofenac Lactose Monohydrate Cellulose, Microcrystalline Sodium Carbonate Colloidal Silicon Dioxide Crospovidone Poloxamer 407 Magnesium Stearate Alcohol Hypromellose 2208 (15000 MPA.S) Carbomer 941 Hypromellose 2910 (6 MPA.S) Alcohol Methylene Chloride Hypromellose 2910 (5 MPA.S) Titanium Dioxide Ethylcelluloses Diethyl Phthalate Film-coated white oblong tablet UT;CR;CT"],"storage_and_handling":["STORAGE Preserve in tight containers. Store at room temperature not exceeding 30 o C. SHELF LIFE Three (3) years from manufacturing date. Do not exceed the expiry date for use printed on the box ."],"version":"7"}